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Clinical Relevancy Statement
The findings that parenteral nutrition (PN) administration 
with and without lipids led to specific histologic and bio-
chemical changes in both the liver and adipose compart-
ments suggest that newer strategies for PN administration 
are needed to avoid such negative side effects. Both changes 
have a close resemblance to metabolic syndrome, and nor-
mally they develop within a week of administration. These 
metabolic abnormalities in both glucose and lipids might 
therefore help to elucidate the etiology of PN-related 
complications.
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Introduction
Parenteral nutrition (PN) is useful for patients who can-
not tolerate enteral intake.1 However, PN is associated several 
adverse problems, including the development of PN-associ-
ated liver disease (PNALD), which can lead to liver dysfunc-
tion, hepatobiliary complications, cholestasis, and steatosis.2-3 
PNALD is a devastating complication and is associated with 
an increased incidence of sepsis, higher mortality rates, and 
the potential to develop irreversible liver injury.4-9 However, 
the mechanisms that lead to PNALD remain unknown. 
Rodent models of PN show a decline in MDR2 expression.10-11 
MDR2 is a key factor that transports bile from the hepatocyte 
to the bile canaliculi, and this decline may be a contributing 
factor in the development of PNALD. Interestingly, a decline 
in the MDR2 expression has also been reported to correlate 
with changes in the expression of peroxisome proliferator-
activated receptors (PPARs).11 PPARs are a group of 3 nuclear 
receptor isoforms, PPAR-α, PPAR-γ, and PPAR-δ. PPARs play 
critical physiologic roles as lipid sensors and regulators of 
lipid metabolism.12 The upregulation of PPAR-α induces 
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increased triglyceride (TG) levels and decreased high density 
lipoprotein (HDL) levels.13 PPAR-γ is associated with insulin 
resistance.14 A mild down regulation of PPAR-γ induces 
decreased TG levels and an increased expression of adipo-
nectin. Adiponectin is an adipocyte-derived hormone that is 
present in plasma and sensitizes the organism to insulin as 
well as acts as an anti-inflammatory factor. In contrast, severe 
down-regulation of PPAR-γ leads to increased TG levels and 
decreased adiponectin levels. More potent synthetic PPAR 
ligands, including fibrates and thiazolidinediones, can modu-
late MDR2 abundance15 and have proven effective for the 
treatment of dyslipidemia and diabetes.16 Because of these 
critical metabolic activities, PPARs have been identified as 
key factors in metabolic syndrome.
Metabolic syndrome is defined as abdominal obesity, 
dyslipidemia, proinflammatory cytokine state, and insulin 
resistance.17,18 Metabolic syndrome can lead to a number 
of clinical complications, including hyperglycemia, hyper-
triglyceridemia, hypertension, diabetes, cholestasis, steato-
sis, thrombosis, and infection.17 Importantly, adiponectin, 
other adipocytokines, and PPARs may be either upregulated 
or downregulated with metabolic syndrome,19 whereby adi-
ponectin levels are decreased in patients with visceral obe-
sity, unlike other factors, which are typically increased by 
lipids in metabolic syndrome. Adiponectin in particular has 
attracted attention in the pathophysiology of metabolic 
syndrome. The action of adiponectin extends to the insulin-
sensitizing function, anti-inflammatory properties, and 
antiatherogenic function.20
Interestingly, some of the metabolic problems observed 
with the administration of PN have similarities to those 
observed in patients developing metabolic syndrome. Com-
mon to both conditions is a large intake of glucose and fat. 
It is also possible that the administration of lipids in PN solu-
tion may be a contributing factor to some of these metabolic 
derangements, as PN with lipids has been shown to increase 
hepatocyte apoptosis.21 The stimulation of lipid metabolic-
associated genes such as PPARs may inhibit hepatic apopto-
sis.22 Other agonists of lipid metabolic-associated genes may, 
however, lead to an increase in hepatocyte apoptosis.23
The aim of this study was to test the hypothesis that 
PN administration would lead to metabolic abnormalities 
of glucose and lipids and subsequently lead to an altered 
abundance of adipocytokines and their related gene expres-
sion in a rat model. This study also investigated whether 
some or all of these PN-associated metabolic abnormalities 
are related to parenteral lipid administration.
Materials and Methods
Animals
The treatment of the rats and our study was approved by 
the Ethics Review Committee for Animal Experimentation 
of Osaka University School of Medicine in Osaka, Japan. 
Male Wister rats (n = 26; weight range, 200–220 g), pur-
chased from Clea Japan Co (Tokyo, Japan) were used. 
Rats were maintained in pathogen-free conditions in the 
animal facility. The experimental animals had free access 
to standard rat food (Oriental Yeast Co, Osaka, Japan) 
and tap water, while in their cages, and were acclimatized 
to standard conditions in the laboratory with approxi-
mately 40% to 60% humidity at room temperature of 23oC. 
The rats were subjected to alternate 12-hour light/dark 
cycles.
Experimental Protocols/Procedures
After an overnight fast, the rats (n = 26) were anesthetized 
with the intraperitoneal injection of 90 mg/kg of ketamine. 
Catheterization and administration of PN was similar to 
that described previously.10-11,21,24 Briefly, the neck and inter-
scapular regions were shaved and prepared in a sterile man-
ner for catheterization. A silastic tube (inner diameter, 0.5 
mm; Kaneka Medix Co, Osaka Japan) was inserted through 
the right jugular vein. The catheter was tunneled subcuta-
neously and brought out through the skin of the midscapu-
lar region.
After catheterization, rats were maintained in individual 
metabolic cages and infused with normal saline in addition 
to standard laboratory rat chow and water ad libitum. After 
24 hours, all rats were separated into 3 groups. The control 
group (n = 5) received the same intravenous (IV) physiologic 
saline at 80 mL/day in addition to standard laboratory rat 
chow (ie, approximately 350 kcal/100 g [1,465 kJ/100 g], 
crude protein 27%, crude fat 5%, crude ash 7%, crude fiber 
4%, nitrogen free extract 55%; Clea, Japan) and water ad 
libitum. The PN–lipid group (n = 7) received a standard 
IV PN solution at 80 mL/d without any enteral nutrition 
(EN). The PN solution contained a balanced mixture of 
glucose, amino acids, electrolytes, minerals, and vitamins, 
as previously described.25 In a separate group of rats, PN 
was administrated with IV fats (PN+L group, n = 9). To 
allow for a matched amount of energy delivery between the 
groups, 10% of glucose calories were exchanged for fats 
(Intralipos 10%; Otsuka Pharmaceutical Co, Ltd, Tokyo, 
Japan) in the PN+L group (Table 1). The amount of non-
protein calories given was 220–230 kcal/kg/day as glu-
cose.25-26 Multivitamins and electrolytes also were included 
in the PN solutions. After 7 days of total continuous infu-
sion, all mice were killed. Blood samples were collected 
aseptically from the inferior vena cava and centrifuged 
(13,000 g for 5 minutes at 4°C), and thereafter plasma was 
collected. Liver and adipose tissue from mesenteric (visceral 
fat) specimens were obtained. The samples were preserved 
either with 10% buffered formaldehyde (10% formalin in 
phosphate buffer) for histologic examination, or immedi-
ately frozen in liquid nitrogen for mRNA extraction, protein, 
and lipid analyses.
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Histologic Evaluation
Portions of liver were fixed in neutral buffered formalin 
and sectioned at a thickness of 3 to 5 µm using a micro-
tome and were then stained with periodic acid-Schiff (PAS) 
reagent to detect glycogen, and Sudan III reagent to detect 
fat (including triglycerides, some protein-bound lipids, and 
lipoproteins).
Assay of Adipocytokines (Adiponectin, Insulin, 
Leptin, TNF-α, and IL-6)
The abundance of adipocytokines (adiponectin, insulin, 
leptin, tumor necrosis factor [TNF]-α, and interleukin [IL-
6]) in serum, liver, fat was measured by enzyme-linked 
immunosorbent assay (ELISA) following the manufac-
turer’s instructions. The rat/mouse adiponectin ELISA Set 
(Cat.No.41073; Otsuka Co, Japan), the rat/mouse insulin 
ELISA Set (Morinaga, Japan), the rat/mouse leptin ELISA 
Set (Morinaga, Japan), the rat TNF-α ELISA Kit (Cat.
No.ER3TNFA; Endogen, Rockford IL), and the rat IL-6 
ELISA Kit (Cat.No.ER2IL6; Endogen) from BD Biosci-
ences were used to quantify each adipocytokines. Duplicate 
serial dilutions were performed for each sample, consisting 
of liver or fat pulverized samples, and mean absorbencies 
were used to determine the concentrations of the cytokines 
in the samples, according to the standard.
Gene Expression of Acdc, AdIPoR1, and 
PPARs
Total RNA was extracted from each liver and fat specimen 
using a kit, (ISOGEN, NIPPON GENE, Tokyo, Japan), 
according to the manufacturer’s guidelines. The RNA con-
centrations were measured spectrophotometrically at 260 
nm. For each sample, 1 mcg of total RNA was used. Reverse 
transcription was carried out using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Fos-
ter City, CA), according to the manufacturer’s guidelines. 
The primers and probes for real-time reverse transcription 
polymerase chain reaction (RT-PCR) were provided by 
Applied Biosystems as ready-to-use mixes. The product 
identification numbers of the mixes were adiponectin 
(acDc, UniGene; Rn.24299, Cat.No.Rn.00595250_m1), 
adiponectin receptor (aDipoR1, UniGene; Rn.14556, 
Cat.No.Rn.01114954_g1), PPAR-α (UniGene; 
Mm.212789, Cat.No.Mm00440937_m1), PPAR-δ 
(UniGene; Mm.328914, Cat.No.Mm.01305435_m1), 
PPAR-γ (UniGene; Mm.3020, Cat.No.Mm.01184321_
m1), and Rat ACTB Endogenous Control (UniGene; 
Rn.4352931E, Cat.No.Rn.01463175_m1). RT-PCR was 
carried out by using the ABI PRISM 7900HT Sequence 
Detection System (Applied Biosystems). A housekeeping 
gene, acTB, served as the endogenous control. The results 
were expressed as a ratio of the target gene to acTB.
Statistical Analysis
Data are represented as the mean ± standard deviation. 
Data analysis was performed using an unpaired t test and 
1-way analysis of variance (ANOVA), with p < .05 consid-
ered significant. Post-hoc intergroup analysis was per-
formed using the Bonferroni t test.
Results
Histologic Analysis With PAS for Glycogen 
detection
Figure 1 shows representative liver sections from control and 
experimental groups stained for glycogen. In Figure 1A, the 
liver section from a control rat shows a normal distribution 
of glycogen in hepatocytes. In the PN–L group, rats received 
larger amounts of glucose to balance energy delivery and were 
noted to have a marked increase in hepatic glycogen granules 
(Figure 1B). Figure 1C represents the liver from a rat in the 
PN+L group. This showed a marked reduction in glycogen 
granules, which was not different than controls.
Histologic Analysis for Intrahepatic Lipids
We next examined the presence and amount of intrahepatic 
lipid deposition. Liver from control rats showed a normal 
Table 1. The Composition of the Nutrients in 3 Groups
Control (Standard Food) PN–L (in 100 mL)    PN+L (in 100 mL)
Protein 22%–23% Glucose (g) 15.7 14.1
Lipid 4.5%–5.5% SAA (g) 5.0 5.0
Mineral mixture 5.5%–6.0% Nitrogen (g) 0.79 0.79
Soluble nonnitrogen 54%–57% Lipid (kcal) 0 6.3
Fiber 3.0% NPC (kcal) 62.8 62.7
Kcal/d 50–60 NPC/N 79.5 79.4
kJ/d 0.21–0.25 kJ/d 0.277 0.277
PN–L, parenteral nutrition without lipids; PN+L, parenteral nutrition with lipids; SAA, sulfur-containing amino acid; NPC, 
non-protein-calorie; N, nitrogen.
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distribution of hepatic lipids (Figure 2A). Similarly, hepatic 
sections from rats in the PN–L group did not show any 
abnormal hepatic lipid deposition (Figure 2B). However, 
rats in the PN+L group showed a much more intense dis-
tribution of lipid droplets in the liver compared with control 
and PN–L groups (Figure 2C).
Serum Adipocytokines
Both PN groups showed a 30% increase in serum adipo-
nectin levels compared with controls (Figure 3). Serum 
insulin and leptin levels did not show any differences 
between the study groups (data not shown).
Adipocytokine Expression in Liver and Fat
Figure 4 shows the adipocytokine expression in the liver 
from each study group. Insulin and leptin levels were rela-
tively low in all groups. Abundance of TNF-α and IL-6 were 
significantly decreased in the PN+L group compared with 
the PN–L and control groups.
 
Figure 1.  Representative hepatic sections stained with periodic 
acid-Schiff. (A) Slide from a control (chow fed) rat shows a nor-
mal distribution of glycogen in the hepatocytes. (B) Hepatic 
section from a rat treated with PN–lipid, and shows a strong 
increase in glycogen granules. (C) Liver from a PN+L group rat 
shows a reduction in glycogen granules to the level of controls.
PN–L, parenteral nutrition without lipids; PN+L, parenteral 
nutrition with lipids.
 
Figure 2.  Representative hepatic sections stained with Sudan III. 
(A) Slide from a control rat does not show any abnormal distribu-
tion of lipids in the liver. (B) Hepatic section of a rat in the 
PN–lipid group does not show any accumulation of lipid drops. 
(C) Hepatic section from a rat in the PN–lipid group shows a 
strong increase in lipid droplets.
PN–L, parenteral nutrition without lipids; PN+L, parenteral 
nutrition with lipids.
 
Figure 3.  Concentration of serum adiponectin levels. Note 
adiponectin increased in both PN groups compared with the 
control group. Values are mean ± standard deviation.
PN, parenteral nutrition; PN–L, parenteral nutrition without 
lipids; PN+L, parenteral nutrition with lipids.
ap < .05 vs control group.
 
Figure 4.  Hepatic adipocytokines insulin, leptin, TNF-α, 
and IL-6 were assayed by ELISA. Insulin and leptin levels 
were relatively low in all groups. Abundance of TNF-α and 
IL-6 decreased in the PN+L group, compared with controls.
ELISA, enzyme-linked immunosorbent assay; IL, interleukin; 
PN–L, parenteral nutrition without lipids; PN+L, parenteral 
nutrition with lipids; TNF-α, tumor necrosis factor α.
ap < .05 vs control group.
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Figure 5 shows adipocytokine expression in fat tissue. 
Leptin was strongly expressed in fat. TNF-α levels were 
decreased in both PN groups compared with the control group. 
IL-6 levels did not significantly change between groups. Insulin 
levels were relatively low in all groups, but compared with the 
other 2 groups was significantly increased in the PN+L group.
mRNA Abundance of Adiponectin (Acdc) and 
the Receptor Gene (AdIPoR1) in Liver and Fat
To further understand the control of lipid metabolism 
with PN, the regulatory control factors for adipocytokines 
were examined (Figure 6). Adiponectin is encoded by the 
adipocyte C1q and collagen domain containing (acDc) 
gene. The expression of the acDc gene was 104-fold 
stronger in fat compared with the liver. The abundance 
of acDc in the fat was significantly increased (10%–20%) 
in both PN groups in comparison with controls. The adi-
ponectin receptor ADIPOR1 mediates PPAR-α ligand 
activities as well as fatty acid oxidation and glucose uptake 
by adiponectin. ADIPOR1 (AR-1) expression was signifi-
cantly decreased (10%–30%) in the liver in both PN 
groups.
mRNA Abundance of PPAR 
Genes in Liver and Fat
As the PPAR family can modulate adiponectin levels, the 
abundances of these family members were next examined 
in liver and fat tissues (Figure 7). In fat tissue, PPAR-γ 
expression was more strongly expressed than other PPAR 
genes (PPAR-α and PPAR-δ). In the liver, PPAR-α and 
PPAR-δ expression significantly declined (10%–30%) in 
the PN+L group compared with controls. Conversely, 
PPAR-γ expression in the liver significantly decreased in 
both PN groups compared with controls. However, the 
decline in the PN–L group was several times greater than 
the PN+L group.
Figure 5.  Fat adipocytokines insulin, leptin, TNF-α, and IL-6 
assayed by ELISA. Abundance of TNF-α decreased in both of PN 
groups compared with controls. The expression of insulin was 
relatively low in all groups, but increased in the PN+L group 
compared to the other 2 groups.
ELISA, enzyme-linked immunosorbent assay; IL, interleukin; 
PN–L, parenteral nutrition without lipids; PN+L, parenteral 
nutrition with lipids; TNF-α, tumor necrosis factor α.
ap < .05 vs control group.
Figure 6.  Hepatic ADIPOR1 (AR-1) abundance (top panels) 
significantly decreased (10%–30%) in both PN groups. The 
expressions of acDc gene was 104-fold stronger in the fat than 
the liver. Expression of acDc in fat tissue increased in both PN 
groups (bottom panels) compared with controls.
acDc, adiponectin encoding gene; AR-1, adiponectin recep-
tor gene 1; PN, parenteral nutrition; PN–L, parenteral nutri-
tion without lipids; PN+L, parenteral nutrition with lipids.
ap < .05 vs control group.
Figure 7.  Hepatic PPARs (PPAR-α, PPAR-δ, and PPAR-γ) 
expression significantly declined in the PN+L group compared 
to controls. In the PN–L group, hepatic PPAR-γ abundance also 
decreased significantly compared with controls. In fat tissue, 
only PPAR-γ was noted to be strongly detected in all groups but 
did not vary significantly between groups.
acTB, β-actin; mRNA, messenger RNA; PN–L, parenteral nutri-
tion without lipids; PN+L, parenteral nutrition with lipids; PPAR, 
peroxisome proliferator-activated receptor.
ap < .05 vs control group.
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Discussion
The clinical spectrum of PNALD includes cholestasis, ste-
atosis, cholelithiasis, sepsis, hepatic fibrosis, biliary cirrhosis, 
the development of portal hypertension, and liver failure.27-28 
However, the pathogenesis of these disorders remains 
unclear. The present study utilized 2 PN rodent models to 
better study this question. The histologic findings of the liver 
exhibited glycogen accumulation in the PN–L group and a 
marked increase in hepatic lipids in the PN+L group. Both 
changes were quite distinct from chow-fed rats which indi-
cates the development of a vesicular fatty liver—findings 
that may mimic changes seen in clinical patients. Such a 
similar pattern may be seen in patients suffering from meta-
bolic syndrome.29-30 The early steatotic development of fatty 
liver may be because of various mechanisms, including 
increased lipid uptake, increased lipid transport to the liver, 
increased lipid synthesis, impaired transport from liver, and 
the decreased oxidation of fatty acids.30-31 In addition, exces-
sive glucose administration may lead to steatosis attributed 
to hepatic glycogen accumulation. Excessive or continuous 
energy delivery results in hyperinsulinemia, which suppresses 
fatty acid oxidation and the acceleration of fatty acid synthe-
sis from glucose.32 Although clearly distinct processes, such 
metabolic changes may occur either with PN or in metabolic 
syndrome. Recently, long-term PN has been reported as one 
of the risk factors for the development of nonalcoholic ste-
atohepatitis (NASH).33 A likely contributor to NASH in these 
patients may be continuous administration of PN, which 
leads to hepatic accumulation of glycogen and lipids because 
of an inability to adequately metabolize base substrates.
Generally, lipids should be taken into the lymphatic 
reticular systems via the intestinal route. However, the 
direct IV infusion of fats via PN might result in stacked 
lipid drops in peripheral capillaries, including the liver, 
similar to that seen in Figure 2C. The mechanisms that 
cause these changes may relate to an altered regulation of 
the genes that modulate fat in the liver. This prompted us 
to pursue these subsequent investigations.
Adiponectin is a key molecule in obesity-related meta-
bolic syndrome and a novel adipocytokine. Its abundance 
negatively correlates with the parameters of metabolic syn-
drome, where a lack of adiponectin may accelerate steato-
hepatitis as well as result in increased serum TNF-α 
expression.20 Interestingly, increased adiponectin expression 
was detected in both PN study models. Such an increase 
may be a corrective attempt to adjust for the constant deliv-
ery of substrate to the liver. The increased expression of 
adiponectin found in this study is clearly different from 
those changes found in metabolic syndrome, and thus our 
PN model is distinct from many of the aspects of this syn-
drome. An increase in adiponectin has been reported in 
models of carbon tetrachloride-treated mice34 and in human 
patients with liver cirrhosis.35-38 The adiponectin receptor 
ADIPOR1 actually decreased in both PN groups. The lack 
Figure 8.  Summary of the regulatory processes that are altered 
by PN in adipose tissue. Large adipocytes change to the small 
cells, which secrete adiponectin, under dieting, cachexia, 
standard PN, or antimetabolic conditions. Conversely, the number 
of large cells increase with obesity, stress, or excessive PN and 
secrete TNF-α and IL-6.
acDc, adiponectin encoding gene; IL, interleukin; PN, 
parenteral nutrition; PPAR, peroxisome proliferator-activated 
receptor; TNF-α, tumor necrosis factor α.
*Dieting, cachexia without any stress, standard PN.
#Metabolic syndrome, obesity, stress, or excessive PN.
Figure 9.  Summary of the regulatory processes that are altered 
by PN in liver. PN administration decreased AR-1/PPARs/ 
MDR2 expressions, in spite of the increased adiponectin levels. It 
might lead the metabolic suppressions of fatty acids in liver and 
the decline of PC secretion into bile. Moreover, increased insulin 
levels (with PN+L) might lead to the storage of glycogen in liver. 
ACETLY COA, acetyl coenzyme a; MDR2, multidrug-resistance 
2 P-glycoprotein; VLDL, very low-density lipoprotein; PN, 
parenteral nutrition; PC, phospholipids (phosphatidyl choline); 
AR-1, adiponectin receptor gene 1; PPARs, peroxisome prolifera-
tor-activated receptors; PN+L, parenteral nutrition with lipids; 
TG, triglycerides.
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of a synthetic balance between increased serum adiponectin 
levels and decreased hepatic ADIPOR1 expression39-40 might 
be characterized as a key element in the metabolic abnor-
mality in our PN models (Figures 8 and 9). In other words, 
the loss of receptor expression may lead to inadequate adi-
ponectin action despite the increased serum levels. Signaling 
via ADIPOR1 helps to mediate PPAR action.
Decreased PPAR abundance may lead to functional 
insulin resistance.41 Signaling via PPAR-γ ligand increases 
expression and plasma concentrations of adiponectin.42 The 
current study showed decreased PPAR-γ expression in the 
liver of our PN animals, particularly in the PN–L group. 
PPAR-γ is known as a thrifty gene.43,44 The stimulation of 
such genes results in energy storage, while the absence of 
the gene affects energy consumption. Thus, the observed 
decline in PPAR-γ might be one of the mechanisms respon-
sible for the glycogen/lipid accumulation in the liver of the 
PN group animals (Figures 1 and 2).
The PN models in the present paper showed significantly 
decreased expression of TNF-α compared with controls. 
Generally, TNF-α is produced more in insulin-resistant con-
ditions and dose-dependently reduces the expression of adi-
ponectin in adipocytes by suppressing its promoter activity.42 
Interestingly, the percentage of monocytes producing TNF-α 
and IL-6 after LPS stimulation are lower in infants on PN 
than both control infants and adults.45 This may explain one 
of the mechanisms responsible for the reduced inflammatory 
response to the bacterial challenge in infants on PN in com-
parison with enterally fed infants or adults.45 In addition, 
decreased TNF-α and IL-6 levels are characteristic of patients 
with cirrhosis, which has also been shown to correlate with 
elevated circulating adiponectin levels.35 The PN+L model 
studied here might also resemble this situation because of 
the decreased TNF-α and IL-6 levels and increased adipo-
nectin level. The precise relevance of these altered cytokines 
on the changes in adiponectin and downstream factors will 
require further work in the future. A summary of the meta-
bolic and regulatory mechanisms are shown in Figures 8 and 
9. Despite end-point hepatic changes similar to those 
observed in metabolic syndrome, other regulatory differences 
are also highlighted in these figures.
In conclusion, this study showed that PN led to specific 
alterations in the expressions of metabolic adipocytokines and 
PPARs in the rat model. PN administration with and without 
fat led to specific histologic and biochemical changes in the 
liver and adipose compartments of the rat. These metabolic 
abnormalities in both glucose and lipids might therefore help 
to elucidate the etiology of PN-related metabolic complica-
tions. The results also may suggest that newer strategies of 
PN administration are needed to avoid such derangements.
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